Development of Antifungal Peptides against Cryptococcus neoformans; Leveraging Knowledge about the <i>cdc50Δ</i> Mutant Susceptibility for Lead Compound Development-Reference-Cited by-同舟云学术

Development of Antifungal Peptides against Cryptococcus neoformans; Leveraging Knowledge about the cdc50Δ Mutant Susceptibility for Lead Compound Development

Published:2022-04-27 Issue:2 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Tancer Robert J.¹,Wang Yina²,Pawar Siddhi²,Xue Chaoyang²,Wiedman Gregory R.¹^ORCID

Affiliation:

1. Department of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey, USA

2. Public Health Research Institute, Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA

Abstract

The authors have developed a lead compound peptide antifungal drug targeting a protein from the organism Cryptococcus neoformans . Binding of the drug to the target fungal protein causes charged lipid molecules to be retained on the surface.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.00439-22

Reference34 articles.

1. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis

2. Antifungal use in HIV infection

3. Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia